065660.KQライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 7月 2024 @ 13:56):
Our systems believe the stock currently is undervalued by 0.00% compare to its pairs and should correct upwards.

Stats
本日の出来高	11 981
平均出来高	49 707
時価総額	145.58B
EPS	KRW-58.72 ( Q1 \| 2024-03-31 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	KRW26.91 (0.18%)

相関 (AI algo v.1.1b): Undervalued: 0.00% KRW14 960 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: 0.29 (neutral)

短: 0.69 (moderate)

Signal:(51.635) Neutral

Anterogen.Co.,Ltd. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Anterogen.Co.,Ltd. 相関 - 通貨/商品

0.60
( weak )

0.47
( neutral )

0.23
( neutral )

-0.23
( neutral )

-0.38
( neutral )

0.49
( neutral )

Anterogen.Co.,Ltd. 財務諸表

Annual	2023
収益:	KRW6.50B
総利益:	KRW2.21B (34.05 %)
EPS:	KRW-291.93

FY	2023
収益:	KRW6.50B
総利益:	KRW2.21B (34.05 %)
EPS:	KRW-291.93

FY	2022
収益:	KRW6.59B
総利益:	KRW2.62B (39.70 %)
EPS:	KRW-705.88

Financial Reports:

No articles found.

Anterogen.Co.,Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material. In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.